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ABSTRACT
Background: Osimertinib is efficacious in lung cancer patients with epidermal 
growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR 
tyrosine kinase inhibitors due to EGFR-T790M mutation (T790M). We sought to 
describe T790M changes in serum/plasma during osimertinib therapy and correlate 
these changes with treatment outcomes.
Material and methods: Serum/plasma from EGFR-mutant lung cancer patients 
with T790M-AR was collected before and during osimertinib treatment. Changes in 
T790M were evaluated using a peptide-nucleic acid-PCR assay, and correlated with 
clinical and radiographic response.
Results: Thirteen patients were included. Median time on osimertinib treatment 
was 10.6 months with a median progression-free survival of 13.6 months. Best 
response to osimertinib was partial response (PR), stable disease (SD) or progression 
(PD) in 46.1%, 30.8% and 23.1% of patients, respectively.
Most of the patients were paucisymptomatic at baseline. Symptom improvement 
was reported in 66.6% of responder patients; while symptoms remained stable in 
75% of patients with SD, and 66% of patients with PD had clinical deterioration.
Three patterns of T790M changes during osimertinib treatment were identified. 
T790 remained detectable with PD or a short-lasting SD in 15.4% of the patients. 
T790M disappeared in 69.2% of patients with PR or SD. T790M disappeared, despite 
clinical and/or radiographic progression in 15.4% of the patients.
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Conclusion: Changes of T790M in serum/plasma in EGFR-mutant lung cancer 
patients with T790M-AR might be a useful marker of symptomatic and radiographic 
outcome to osimertinib. Longer follow-up is needed to establish if subsequent 
emergence of T790M could be a marker of resistance.
INTRODUCTION
First- and second-generation tyrosine kinase 
inhibitors (TKIs), erlotinib, gefitinib and afatinib, as well 
as the combination of erlotinib and bevacizumab, have 
demonstrated a clinically meaningful benefit as upfront 
therapy in patients harboring epidermal growth factor 
receptor (EGFR) mutations [1]. However, despite an 
initial clinical benefit, acquired resistance (AR) invariably 
develops, mainly due to the emergence of the secondary 
mutation EGFR-T790M (T790M) [2, 3]. Several clinical 
trials have tested different drugs to treat patients with 
AR to first- and second-generation TKIs with modest 
results [4–10]. Therefore, standard chemotherapy and best 
supportive care have remained the main treatment options 
for these patients. Currently, third-generation TKIs with 
the ability to inhibit both T790M and the sensitizing 
EGFR mutations have entered the clinical scenario [11, 
12]. Osimertinib, a third-generation TKI, has demonstrated 
a clinically meaningful benefit in patients with EGFR 
mutations who have developed AR to TKIs. In clinical 
studies with osimertinib, patients with T790M-positive 
tumors reported an overall response rate (ORR) of 61% 
and median progression-free survival (mPFS) of 9.6 
months, with a favorable toxicity profile [12]. Recently, 
osimertinib has also demonstrated significant advantages 
in terms of response and progression-free survival in 
EGFR-mutant lung cancer patients treated in first line [13].
One limitation for EGFR mutation testing is the 
scarcity of tumor tissue in patients with advanced disease. 
Detecting EGFR mutations in serum or plasma has been 
proposed as an alternative to tumor tissue. Using serum 
and plasma for molecular testing relies on the fact that 
mutant DNA fragments from necrotic neoplastic cells are 
freely circulating in blood [14]. As tumors become more 
aggressive there is more necrosis, leading to an increase 
in the absolute amount of circulating DNA that can be 
detected. Initial studies report that EGFR mutations could 
be detected in paired tumor and plasma samples in more 
than 70% of the patients with EGFR-mutant lung cancer 
[15]. Moreover, different sources of tumor DNA present in 
the peripheral blood provide dynamic information of the 
disease, reflecting not only the assessment of the primary 
tumor, but also of the metastatic sites.
Different techniques, including emulsion 
polymerase chain reaction (PCR) (ddPCR and ddPCR 
Beaming), reverse transcription PCR (RT-PCR), peptide-
nucleic acid (PNA), amplification refractory mutation 
system (ARMS), and Scorpion, have been used to detect 
EGFR mutations with a sensitivity ranging from 61% to 
93% for the sensitizing mutations and from 41% to 81% 
for T790M [16]. EGFR mutations in serum and plasma 
have been used to monitor the evolution of the sensitizing 
mutations during treatment. In addition, the presence of 
EGFR mutations in serum and plasma has been associated 
with poorer prognosis [17, 18]. Recently, peripheral 
blood has become a useful source to detect the presence 
of T790M as a mechanism of AR [19]. Interestingly, 
T790M can be detected in 70% of the patients with AR 
to first- and second-generation TKIs, which implies that 
tumor rebiopsy could be obviated in patients with positive 
result in plasma. ORR and mPFS were identical in both 
T790M– plasma-positive and tumor-positive patients. In 
addition, urine samples were also evaluated concurrently 
with serum and tissue samples in patients who received 
treatment with rociletinib, another third-generation EGFR-
TKI [20]. Together, urine and plasma samples identified 
a higher proportion of T790M than tissue alone (89% vs. 
75%), and T790M levels decreased in the urine samples of 
patients who responded or had stable disease (SD) shortly 
after starting treatment.
For the present study, we postulated that if 
detected at baseline in serum/plasma once AR to first- 
and second-generation TKIs has occurred, T790M 
mutation could be monitored during treatment with 
a T790M TKI. We hypothesized that this T790M 
monitoring in EGFR mutant patients with a T790M 
mutation as an AR mechanism receiving a T790M 
TKI could indicate response to therapy and subsequent 
progressive disease (PD). Moreover, T790M loss during 
treatment could potentially be correlated to clinical and 
radiographic response and to a quick time to response, 
should T790M disappear in plasma/serum. Thus, the 
follow-up of T790M mutation in plasma/serum could 
be used as a monitoring tool of response in patients 
receiving a T790M inhibitor.
RESULTS
Twenty-one patients with EGFR mutations were 
treated with osimertinib between January 2016 and June 
2017 after confirmed PD to a prior TKI. All the patients 
harbored the T790M mutation, which was evaluated in 
serum/plasma and also in tissue when available. Only 
patients with T790M in serum/plasma were eligible. 
Eight patients were excluded from the analyses because 
T790M was only detected in tissue, but not in serum/
plasma. Thirteen patients were analyzed. Patients who 




All 13 patients included in the analysis, were 
Caucasian, with a median age of 59 years, and had 
adenocarcinoma histology. The type of TKI-sensitizing 
EGFR mutation was a deletion in exon 19 in all the cases 
except 1 patient who harbored an uncommon EGFR 
mutation, G719A in exon 18. Sixty-nine percent of the 
patients had stage IV at diagnosis. The mean number 
of metastatic (M1) sites was 2 (range 1–5), with the 
lung, bone, and brain being the most frequent M1 sites 
(Table 1).
All the patients had previously received a TKI 
(gefitinib in 46.1% of patients, afatinib in 15.4% of 
patients, and erlotinib in 38.5% of patients). The majority 
of patients (76.9%) received an EGFR TKI as first-line 
therapy, with best responses of a PR in 60% of patients 
and SD in 30% of patients (Table 2).
In addition to T790M evaluation in serum/
plasma, 6 patients underwent a rebiopsy after the TKI 
progression. T790M mutation was detected in tissue in 
3 of these patients and was not detected in 2 patients, 
while in 1 patient the rebiopsy tissue was insufficient 
for the molecular analysis. The most frequent M1 sites 
prior to osimertinib treatment were the lung and the 
bone (61.5% and 30.8% of patients, respectively). Most 
(77%) patients presented Eastern Cooperative Oncology 
Group performance status (ECOG PS) 0-1 before starting 
osimertinib (Table 3).
Efficacy
Median patient follow-up time was 45.3 months 
(range 11.2–113.9). Median time on osimertinib therapy 
was 10.6 months (range 1.5–22.5). All 13 patients were 
evaluable for response to osimertinib. Six patients 
presented a partial response (PR) as best response 
(46.1%), while 4 patients presented SD (30.8%), for 
an overall disease control rate of 77%. In 3 out of the 4 
patients with SD (75%), size of tumor lesions according 
to RECIST decreased in the first radiographic evaluation, 
while in 1 patient RECIST increased in 11%, resulting 
in a PD in the subsequent evaluation. Three patients 
presented PD in the first evaluation (23.1%). Two of 
these patients discontinued treatment with osimertinib 
due to radiological and clinical criteria, while in the other 
patient, osimertinib was maintained despite the RECIST 
progression due to clinical benefit.
Median PFS was 13.6 months (95% CI1.1-26.2). 
Median OS was 80.5 months (95% CI 12.8–148.2).
Symptom burden and radiographic response
The majority of patients included in this study 
presented few disease-related symptoms at baseline, with 
a median of symptomatic burden of 2 points (range 0–8) 
according to the proposed symptomatic scale. (Table 4) 
Four patients scored 0 at baseline. Nevertheless, all the 
patients were included in order to evaluate potential 
symptomatic changes during treatment. Four of the 6 
patients (66.6%) who responded to osimertinib improved 
symptoms in the first visit after osimertinib initiation, 
while the other 2 patients remained symptomatically stable 
throughout treatment. One patient experienced transient 
respiratory deterioration in the context of a pulmonary 
embolism and disease progression was ruled out. Among 
patients with SD (n=4) as best response to osimertinib, 3 
patients remained with stable symptoms (75%), while 1 
patient presented a clinical improvement. Among patients 
with PD (n=3) during osimertinib treatment, 2 patients 
experienced clinical deterioration (66.6%) and osimertinib 
was stopped, while 1 patient experience symptomatic 
improvement and osimertinib was maintained despite 
radiographic progression according to RECIST criteria 
(Figures 1 and 2).
T790M in serum/plasma
The majority of patients had blood draws every 6 
weeks according to the routine outpatient visits; however, 
5 patients had blood draws as soon as 3 weeks after 
starting treatment with osimertinib. On the other hand, the 
first blood draw occurred in 3 patients at week 12, 21, and 
24 weeks, respectively after osimertinib initiation. Some 
samples were missing, mainly due to clinical or technical 
reasons (Figure 3).
Overall, we identified three patterns of T790M 
behavior in serum/plasma during treatment with 
osimertinib. In one group of patients (n=9; 69.2%), 
T790M became undetectable in blood during osimertinib 
treatment; in some of the patients this occurred as early as 
3 weeks after therapy initiation (n=3). All of the patients 
included in this group achieved a PR or SD (66.7% and 
33.3%, respectively). Three out of the 9 patients (33.3%) 
included in this group reported symptom improvement, 
while the other 6 (66.7%) remained symptomatic 
stable; although the majority of these patients were 
paucisymptomatic at baseline (88.9%). Only 1 out of 
9 patients (11.1%) presented PD after 6 months on 
osimertinib. In this patient, T790M became detectable 
again in the blood sample drawn at PD. As of the cut-off 
date, 2 patients in this subgroup had died: in 1 patient, the 
death was not considered related to disease progression but 
to an empyema, and the second patient developed a fatal 
pulmonary infection with metachronous pleural effusion. 
The severe condition of this patient prevented from 
performing a thoracentesis to rule out PD in the pleura. 
In both cases, T790M was negative in serum/plasma in 
the last sample drawn before death. Median PFS for the 
patients included on this group was no calculable (NC).
The second group of patients included two patients 
(15.4%) in whom T790M persisted during osimertinib 
treatment throughout the serial blood analyses. These 
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patients presented a short-lasting SD and PD as best 
radiographic response. Median PFS for these patients 
was 1.8 months (95% CI, NC-NC). The symptomatic 
burden remained unchanged for 1 patient while the other 
presented a symptomatic improvement.
Table 1: Clinical and demographic characteristics of 13 patients treated with osimertinib
 N=13n (number of patients) %
Gender   
 Male 3 23.1
 Female 10 76.9
Ethnicity   
 Caucasian 13 100
Age, years   
 Mean (y) 61  
 Median (y) 59  
 Range (y) 37–70  
Histology   
 Adenocarcinoma 13 100
Smoking history   
 Never smoker 10 76.9
 Ever smoker 3 23.1
Initial type of EGFR mutation   
 del 19 12 92.3
 G719A 1 7.7
Stage at diagnosis   
 IA 1 7.7
 IIIA 3a 23.1
 IV 9 69.2
Baseline metastatic sites   
 Mean number of M1 sites 2  
 Range 1–5  
 Baseline M1 sites   
 Lung 9 69.2
 Bone 6 46.1
 Brain 3 23.1
 Lymph nodes 2 15.4
 Liver 1 7.7
 Adrenal gland 1 7.7
 Pleura 1 7.7
a: all patients received CT and PORT.
Abbreviations: CT, chemotherapy; del, deletion; M1, metastatic; PORT, postoperative radiotherapy; y, years.
Oncotarget27078www.oncotarget.com
The third group included two patients (15.4%) 
who presented PD as best response to osimertinib even 
though they experienced a rapid disappearance of T790M 
in serum/plasma. Median PFS for these patients was 1.5 
months (95% CI, NC-NC). One of the patients presented 
clinical benefit to osimertinib and the treatment was 
continued post-progression. Interestingly, the second 
patient presented PD as best response with symptomatic 
Table 2: Therapeutic history of 13 patients prior to osimertinib treatment
 N=13n (number of patients) %
Prior treatments   
 Mean (number of treatments) 1.6  
  Range 1–6  
  Previous TKI 13 100
  Prior CT 5 38.5a, b
 1st line TKI   
  N 10 76.9
  Time to treatment failure (m) 11.25  
  Range (m) 1–19  
  Best response   
  PR 6 60
  SD 3 30
  PD 1c 10
 2nd line TKId   
  N 3 23.1
  Time to treatment failure (m) 29  
  Range (m) 5–76  
  Best response   
  PR 1 33.3
  SD 2 66.6
 3rd line TKI   
  N 1 7.7
  Time to treatment failure (m) 29  
  Best response, PR 1 100
 Type of TKI   
  Gefitinibe 7 53.8
  Afatinib 2 15.4
  Erlotinib 5 38.5
a: This CT regimen included CT for advanced disease.
b: 2 patient received two different CT schedules.
c: This patient presented CNS PD, was treated with WBRT, and continued on TKI with TTF of 5 extra months.
d: Includes 1 patient that was reinduced with TKI.
e: 1 patients was reinduced with gefitinib after erlotinib.
Abbreviations: CNS, central nervous system; CT, chemotherapy; PD, progressive disease; PR, partial response; SD, stable 
disease; TKI, tyrosine kinase inhibitor; TTF, time to treatment failure; WBRT, whole brain radiotherapy.
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deterioration that led to osimertinib discontinuation. 
However, the rebiopsy of the progressive disease 
performed on the liver metastasis prior to osimertinib 
initiation did not reveal the presence of T790M. 
Unfortunately, shortly after disease progression was 
confirmed the patient suffered a stroke with disabling 
sequels that did not allow for subsequent rebiopsy or 
treatment.
DISCUSSION
In the present study, we report the results of 
the prospective evaluation of detecting T790M in 
serum/plasma and its correlation with both clinical 
and radiographic response in patients with lung 
adenocarcinoma harboring EGFR mutations who were 
resistant to first- and second-generation TKIs and who 
were receiving treatment with osimertinib.
Several mechanisms of resistance to first- an 
second-generation TKIs have been described, with the 
acquisition of a T790M secondary mutation as the main 
mechanism of AR [21]. After the approval of osimertinib 
for EGFR-mutant patients with such a resistant mutation, 
its detection becomes of particular interest [22].
Using liquid biopsy as a technique to detect tumor 
abnormalities is of great interest, especially in the lung 
cancer field where the rebiopsy process can be challenging 
due to small sample size or lack of available tumor tissue 
for molecular assessment, which ranges from 15 to 23% 
according to different clinical series, or even the location 
or size of relapsing disease that may difficult the access for 
a new biopsy [23–26]. Moreover, tumor heterogeneity is 
a well-recognized issue that makes a single metastatic site 
not representative of the entire disease in a specific patient 
[21, 27–30]. In this regard, information obtained from 
blood could better depict this tumor heterogeneity and 
evolution of multiple metastatic sites during therapy [31]. 
Table 3: Specific details of the 13 patients prior to osimertinib therapy
 N=13n (number of patients) %
T790M in serum   
 13 100
Tumor rebiopsy   
 no 7 58.8
 yes 6 46.1
 Presence of T790M in tissue 3a 50
 M1 sites prior osimertinib initiation   
 Mean (number of sites) 2.8  
 Range 1–6  
 Progressive M1 sites   
 Lung 8 61.5
 Bone 4 30.8
 Brain 1 7.7
 Pleura 1 7.7
 Meningeal 1 7.7
 Liver 1 7.7
 ECOG PS prior to osimertinib 
initiation   
 0 5 38.5
 1 5 38.5
 2 3 23.1
a: the rebiopsy material was insufficient for molecular testing in 1 patient and T790M was negative is tissue in 2 patients.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; M1, metastatic; PS, performance status.
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Indeed, T790M has been reported exclusively in plasma 
in 31% and 35% of patients whose biopsy was T790M-
negative or indeterminate [19, 24]. Additional advantages 
of the liquid biopsy include the potential use of a marker 
in a dynamic fashion to monitor the efficacy of the drug 
and the early detection of a resistant mutation. Moreover, 
the minimally invasive procedure required makes it of 
special interest for patients.
All of the patients in our study were included on the 
basis of a positive T790M liquid biopsy result. Rebiopsy 
Figure 1: Changes in the symptomatic burden of the 13 patients with lung cancer with EGFR-mutations during 
treatment with osimertinib after acquired resistance to an EGFR TKI due to an EGFR T790M mutation.
W, weeks of therapy.
Patient 1 presented symptomatic worsening in the context of an osteoporotic fracture.
Patient 2 experienced clinical respiratory deterioration due to pulmonary embolism. Progressive disease and osimertinib-related pneumonitis 
were ruled out.
Patient 6 experienced respiratory deterioration at week 90. Osimertinib-related pneumonitis was considered the most likely diagnosis at 
data cut-off.
Patient 8 was admitted due to pneumonia with metachronous pleural effusion with severe respiratory deterioration that led to patient death.
Table 4: Patients’ symptom burden scale based on the main symptoms related to lung cancer
Symptom/grade 0 or none 1 or mild 2 or moderate 3 or severe   
Cough       
Pain       
Weight loss       
Fatigue       
Symptom/grade 0 or none 1 or mild 2 or moderate 3 or severe 4 or life-threatening 5 or death
Anorexia       
Dyspnea       
Hemoptysis       
Based on the CTCAE 4.03 criteria, symptom changes were evaluated by using the information annotated in the medical 
records. Baseline and subsequent symptom burden was calculated by adding the overall score at each scheduled visit 
regarding the items included in the table.
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Figure 2: Radiographic changes according to RECIST 1.1. During treatment with osimertinib in the 13 patients with lung cancer 
with EGFR-mutations after acquired resistance to an EGFR TKI due to an EGFR T790M mutation.
W, weeks of therapy.
Figure 3: T790M evolution in plasma/serum at baseline and during treatment with osimertinib in the 13 patients with 
lung cancer with EGFR-mutations after acquired resistance to an EGFR TKI due to an EGFR T790M mutation.
W, weeks of therapy.
Each line corresponds to one individual patient. The dashed sections correspond to periods of time where the plasma/serum sample 
was not drawn or no result was available.
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could be performed only in 6 patients (46.1%) with a 
confirmative result in 3 of them. According to our series, 8 
patients (38%) who ultimately benefited from osimertinib 
therapy were excluded from the present analysis since 
T790M was not detected in serum, strengthening the need 
of a rebiopsy for those patients whose result in liquid 
biopsy is negative. Moreover, results in serum/plasma 
resulted accurate for therapeutic decisions in 11 out of 
13 patients (85%), regardless of the tissue results, which 
implies that biopsies could be obviated when T790M is 
detected in liquid biopsy such has been proposed [19].
Several studies have demonstrated that liquid 
biopsy can be useful to monitor the disappearance of a 
sensitizing EGFR mutations with EGFR TKI therapy, 
its reappearance after a period of treatment and the 
emergence of the T790M at progression [31, 32]. 
However, little has been reported regarding the behavior 
of T790M in liquid biopsy specifically during treatment 
with osimertinib. Some data in this regard were reported 
in both serum and urine samples in patients treated with 
rociletinib, a third generation TKI no longer available. 
In a small group of patients with serial urine samples, 
T790M levels decreased after a short period of therapy 
[20]. However, no longitudinal changes in plasma were 
reported [33]. Recently, a great spectrum of mechanisms 
of AR to osimertinib have been reported. Again, data on 
longitudinal changes along treatment with osimertinib 
have not been included [34].
In our study, blood samples were drawn periodically. 
According to our results, T790M monitoring during 
osimertinib therapy might predict those patients who 
will or will not respond to this drug. However, a solid 
conclusion cannot be drawn in terms of prediction of 
recurrence according to the reemergence of T70M in 
serum. Longer follow-up would be necessary to confirm if 
T790M mutation reappears in serum once the progression 
occurs, since a high proportion of patients are still on 
treatment with no evidence of progressive disease. 
Moreover, we can hypothesize that a proportion of patients 
will present the T790M once progression occurs, while 
other patients will acquire other mechanisms of resistance. 
T790M serial monitoring could be less useful for the 
subset of patients who develop additional mechanism 
of resistance to third-generation TKIs, including other 
novel mutations such as C797S, small cell lung cancer 
transformation, or MET amplification [34–36]. Our results 
are in contrast to other experiences that have reported 
contradictory results; patients with T790M loss in a cohort 
of 22 patients with AR to osimertinib experienced a shorter 
time to treatment failure than those who maintained 
T790M at resistance, suggesting the subclonal nature of 
this T790M in the blood and the potential emergence of a 
variety of alternative mechanisms of resistance [37].
Regarding the patient with a positive T790M in 
blood but negative in tissue, rapid decrease of T790M 
despite progression could be explained by T790M being 
present as a minor clone with the potential coexistence 
with other mechanisms of AR. Previously, patients with 
such molecular pattern have demonstrated a lower benefit 
from osimertinib compared with those who are plasma and 
tissue positive or plasma negative and tissue positive for 
T790M (19).
General efficacy results in our cohort of patients 
demonstrated a lower RR to osimertinib than reported 
in prior studies [12, 38]. Our series included a more 
pretreated population and patients with PS 2. On the 
other hand, OS in our cohort of patients is longer than 
previously reported. Several factors could potentially 
explain this result, such as the initial early stage diagnosis 
(30%), the presence of del19 (92.3%), the mean number 
of 1.6 metastatic sites and a high proportion of exclusive 
lung disease (46.1%). In addition, one patient has 
presented an outstanding survival that has lasted twelve 
years so far. The survival of this particular patient could 
have potentially influenced the OS of this small cohort of 
patients.
Different plasma genotyping assays have been 
used to isolate cfDNA [16, 18, 39, 40]. Each assay has 
advantages and drawbacks that should be considered. 
General limitations include the cost, the turn-around time, 
the imperfect accuracy, and the clinical context in which 
these tests are used. Ideally, plasma genotyping assays 
should be prospectively validated on paired plasma and 
tissue samples [32]. However, retrospective validation 
using plasma sample from large clinical trials paired with 
tissue sample have also been considered acceptable [18, 
20]. A consistent trend among these well-validated plasma 
genotyping assays is the high specificity and a positive 
predictive value with a more limited sensitivity [16]. The 
advantages of the PNA-based PCR used in our study were 
its availability, its cost, and its favorable turn-around time 
(median of 3 days).
Our study includes several limitations. First, the 
number of patients included is small, but it actually 
reflects clinical practice and the target population being 
not possible to obtain robust conclusion and it should 
be considered an exploratory study. Second, the lack of 
assessment of other non-T790M mediated mechanisms of 
AR to osimertinib once the persistence or reemergence of 
T790M has been ruled out. Third, even after a long follow-
up period, half of the patients were still on treatment and 
free of progression, and the molecular results in serum at 
progression are still unknown.
In conclusion, although our findings must clearly 
be interpreted with caution due to our small sample size, 
we have found that the disappearance or persistence 
of T790M in the serum/plasma in patients with lung 
adenocarcinoma and EGFR mutations and AR to first- 
and second-generation TKIs mediated by T790M may be a 
useful marker of symptomatic and radiographic evolution 
to osimertinib, a third-generation TKI able to target both 
EGFR sensitizing and T790M mutations. Longer follow-
Oncotarget27083www.oncotarget.com
up is needed to establish if the subsequent emergence of 
T790M could be a marker of resistance, at least in the 
proportion of patients who did not develop additional 
mechanism of resistance to osimertinib.
MATERIALS AND METHODS
Patients
Patients with lung cancer with EGFR mutations who 
had progressed to a previous TKI and were selected for 
T790M inhibitor therapy based on positive T790M results 
in serum/plasma plus tissue were included in the analysis. 
The objectives were first, to describe the patient clinical 
characteristics by reviewing their medical records; second, 
to describe the tumor molecular characteristics; third, 
to detail the patients’ symptomatic burden at baseline; 
fourth, to specify patient clinical outcomes by evaluating 
symptom changes during osimertinib treatment using 
the Common Terminology Criteria for Adverse Events 
(CTCAE) 4.03 criteria; fifth, to interpret radiographic 
outcomes using the Response Evaluation Criteria In 
Solid Tumors (RECIST) 1.1 criteria during treatment; 
and seventh, to describe the changes in T790M mutation 
in serum/plasma during osimertinib treatment and try 
to correlate this changes with clinical and radiographic 
response.
All the patients received osimertinib as third-
generation TKI at a standard dose of 80 mg/day orally 
as part of a clinical trial (NCT02474355) or per clinical 
practice. Treatment was maintained until disease 
progression or loss of clinical benefit. Visits were 
scheduled every six weeks. All the patients were followed 
up until death, withdrawal of consent, or loss of follow-
up. Baseline is defined as the patient situation prior to 
osimertinib initiation.
In order to describe changes in the patients’ 
symptom burden and in the absence of formal 
questionnaires of quality of life, a scale that includes the 
main symptoms related to lung cancer was used. This 
scale was designed by reviewing the clinical records and 
assigning points to the following symptoms: cough, pain, 
dyspnea, hemoptysis, fatigue, anorexia, and weight loss 
(Table 4).
RECIST 1.1 was used to evaluate the radiographic 
response during treatment. CT scans were performed 
every 12 weeks, unless any clinical condition required 
additional imaging test to be performed. Response was 
evaluated by investigator.
Molecular analyses
To evaluate T790M in tumor tissue, tumor genomic 
DNA was obtained from formalin-fixed paraffin-
embedded tissue sections from the rebiopsy tumor 
sample. Briefly, samples were reviewed by a pathologist 
to estimate the percentage of neoplastic cells. Five μm 
unstained tissue sections were obtained, and manually 
macrodissected if necessary, to ensure more than 50% of 
neoplastic cell content. DNA extraction was performed 
with the Cobas® DNA sample preparation kit (Roche 
Molecular Systems, Inc, Branchburg, NJ, USA) according 
to the manufacturer’s protocol. The extracted DNA was 
quantified using a DS-11 spectrophotometer (DeNovix 
Inc., Wilmington, DE, USA). EGFR mutations were 
determined with the Cobas® EGFR Mutation Test v2 
(Roche Molecular Systems, Inc, Branchburg, NJ, USA) 
according to the manufacturer’s recommendations. These 
analyses were performed at the Pathology Department of 
Hospital Universitari Germans Trias i Pujol, Badalona, 
Spain.
T790M mutations was tested in all patients in 
both serum and plasma as per our protocol. For T790M 
assessment in serum/plasma, peripheral blood was 
collected from patients in both a 10 ml Vacutainer tube 
for serum and a 10 ml EDTA tube for plasma (Becton 
Dickinson, Plymouth, UK). Tubes were centrifuged twice 
at 2300 rpm for 10 min and the supernatant transferred 
to sterile 1.5 ml tubes and stored at -20ºC until use. 
Circulating DNA was purified, using the QIAamp DNA 
Blood Mini Kit (Qiagen, Hilden, Germany), according 
to the manufacturer’s instructions. This process was 
performed in independent duplicates. T790M mutations 
were examined by allelic discrimination Taqman assay 
performed in presence of a peptide-nucleic acid (PNA) 
designed to completely inhibit the amplification of the wt 
allele. All circulating-free DNA (cfDNA) samples were 
also tested without PNA to confirm the presence of DNA.
Primers, probes and PNA were described previously 
by our group [18, 41]. Blood draws were performed before 
starting osimertinib and periodically during the treatment. 
Blood draws were schedule every 6 weeks according to 
the clinical visits. These analyses were performed at the 
Molecular Biology Laboratory (Dr Rosell) at the Institute 
Germans Trias i Pujol (IGTP), Badalona, Spain.
All the patients signed the informed consent for 
their participation in the study, which included the clinical 
chart review, the molecular testing in the rebiopsy, when 
available, and periodic blood drawn and serial molecular 
testing. Approval was obtained from the IRB of our 
institution (RegTumTor2014).
Statistical analyses
Data were described in terms of ranges, medians, 
frequencies and percentages. Overall survival (OS) was 
defined as the time from the initial diagnosis to death 
from any cause. PFS was defined as the time from starting 
osimertinib to documented disease progression or death. 
Time on treatment (ToT) was calculated from the stating 
date to the last dose of osimertinib. Patients who were still 
alive at the date of last contact were censored. OS and 
Oncotarget27084www.oncotarget.com
PFS were calculated with the Kaplan-Meier method. All 
statistical calculations were done with Microsoft Excel 
2007 (Microsoft Corporation, NY, USA) and Statistical 
Package for the Social Sciences (SPSS Inc., Chicago, IL, 
USA) version 24 for Microsoft Windows.
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